合并少肌症对肝硬化患者行经颈静脉肝内门体分流术后发生肝性脑病的影响

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 602-605.

合并少肌症对肝硬化患者行经颈静脉肝内门体分流术后发生肝性脑病的影响

于蕊, 孙倩, 师强伟, 王春峰, 姚建宁, 张连峰

450052 郑州大学第一附属医院消化内科(于蕊,孙倩,王春峰,姚建宁,张连峰),心内科(师强伟)

收稿日期:2021-01-13 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 师强伟,Email:shiqiangwei2007@126.com
基金资助:
河南省自然科学基金(202300410408)

Sarcopenia may predict the occurrence of hepatic encephalopathy in patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt

YU Rui¹, SUN Qian¹, SHI Qiang-wei², WANG Chun-feng¹, YAO Jian-ning¹, ZHANG Lian-feng¹

1. Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Henan 450052, China;
2. Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, 450052, China

Received:2021-01-13 Online:2021-06-30 Published:2021-07-19
Contact: SHI Qiang-wei,Email:shiqiangwei2007@126.com

摘要/Abstract

摘要： 目的探讨合并少肌症对于肝硬化患者行经颈静脉肝内门体分流术后发生肝性脑病的影响。方法回顾性分析2015年1月至2019年8月行经颈静脉肝内门体分流术的患者301例,收集其术前及术后资料,通过CT图像及软件分析测量L3层面的骨骼肌面积定义骨骼肌质量指数,采用二元Logistic回归分析发生肝性脑病的危险因素。结果接受经颈静脉肝内门体分流术的肝硬化患者中,少肌症的发生率为63.8%(192/301)。年龄(OR:1.088, 95%CI:1.024~1.156)、MELD评分(OR:1.004, 95%CI:1.003~1.005)、HE病史(OR:1.922, 95%CI:1.487~2.357)及合并少肌症(OR: 2.745, 95%CI: 2.311~2.902)是术后HE发生的独立危险因素。结论经颈静脉肝内门体分流术,术前合并少肌症可预测肝硬化患者经颈静脉肝内门体分流术后术后肝性脑病的发生。

关键词: 少肌症, 肝硬化, 经颈静脉肝内门体分流术, 肝性脑病

Abstract: Objective To investigate the predictive value of sarcopenia on the occurrence of hepatic encephalopathy (HE) in patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt (TIPSS).Methods A retrospective analysis of 301 patients who underwent TIPSS therapy from January 2015 to August 2019 were enrolled in these study. The skeletal muscle areas of the patients at the L3 level were measured by CT images and were analyzed by software to define sarcopenia. Risk factors for HE were analyzed by binary logistic regression.Results Among patients with liver cirrhosis who underwent TIPPS, the incidence of sarcopenia was 63.8%. Age (OR:1.088, 95%CI:1.024-1.156), MELD score (OR:1.004, 95%CI:1.003-1.005), HE history (OR:1.922, 95%CI: 1.487-2.357) and sarcopenia (OR: 2.745, 95%CI: 2.311-2.902) were independent risk factors for postoperative HE.Conclusion The incidence of sarcopenia in cirrhotic patients underwent TIPSS is relatively high. Sarcopenia may predict the occurrence of HE in liver cirrhotic patients after TIPSS surgery. Caution should be taken on such patients.

Key words: Sarcopenia, Liver cirrhosis, Transjugular intrahepatic portosystemic shunt, Hepatic encephalopathy

于蕊, 孙倩, 师强伟, 王春峰, 姚建宁, 张连峰. 合并少肌症对肝硬化患者行经颈静脉肝内门体分流术后发生肝性脑病的影响[J]. 肝脏, 2021, 26(6): 602-605.

YU Rui, SUN Qian, SHI Qiang-wei, WANG Chun-feng, YAO Jian-ning, ZHANG Lian-feng. Sarcopenia may predict the occurrence of hepatic encephalopathy in patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt[J]. Chinese Hepatolgy, 2021, 26(6): 602-605.

参考文献

[1] Li M, Xu X. Researches on the prevention and treatment of bleeding gastroesophageal varices secondary to portal hypertension in patients with cirrhosis. Zhonghua Gan Zang Bing Za Zhi, 2015,23:247-249.
[2] Sankar K, Moore CM. Transjugular intrahepatic portosystemic shunts. JAMA, 2017,317:880.
[3] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology,2014,60:715-735.
[4] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing, 2010,39:412-423.
[5] Ponziani FR, Gasbarrini A. Sarcopenia in patients with advanced liver disease. Curr Protein Pept Sci, 2018,19:681-691.
[6] Merli M, Giusto M, Lucidi C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis, 2013,28:281-284.
[7] Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol, 2012,10:166-173, 173 e161.
[8] Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003,124:91-96.
[9] Chinese Society of Hepatology CMA. Chinese guidelines on the management of liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi, 2019,27:846-865.
[10] Chinese Society of Hepatology CMA. [Guidelines on the management of hepatic encephalopathy in cirrhosis]. Zhonghua Nei Ke Za Zhi, 2018,57:705-718.
[11] Yu R, Shi Q, Liu L, et al. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. BMC Gastroenterol, 2018,18:51.
[12] Hsu CS, Kao JH. Sarcopenia and chronic liver diseases. Expert Rev Gastroenterol Hepatol, 2018,12:1229-1244.
[13] Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol, 2015,6:e102.
[14] Olde Damink SW, Jalan R, Redhead DN, et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology, 2002,36:1163-1171.
[15] Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol, 2012,8:457-465.
[16] Yu R, Shi QW, Wang CF, et al. Research advances in the relationship between nonalcoholic fatty fiver disease and sarcopenia. Zhonghua Gan Zang Bing Za Zhi, 2019,27:725-727.
[17] Miller AM, Wang H, Bertola A, et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology, 2011,54:846-856.
[18] Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 2012,481:463-468.
[19] Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol, 2013,59:557-562.